4DMT reports encouraging Phase 2 PRISM interim outcomes for Intravitreal 4D-150 in diverse wet AMD patients, confirming positive safety and strong clinical efficacy.

Bayer reveals promising primary results for NUBEQA® (darolutamide) from a Phase III study in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Genentech Reports Promising Phase I Outcomes for Oral GLP-1 Receptor Agonist CT-996 in Obesity Treatment.

NexThera Co., Ltd. announced the submission of a Phase 1/2a Investigational New Drug application to the U.S. Food and Drug Administration for NT-101.

Celldex Therapeutics launches worldwide Phase 3 trial of Barzolvolimab for chronic spontaneous urticaria patients.

Novo Holdings spearheads $100 million Series C investment in Asceneuron to propel innovative Alzheimer’s treatment forward.

Biosyngen's BRG01 moves to Phase II trial, pioneering autologous EBV-specific CAR-T for recurrent/metastatic nasopharyngeal carcinoma solid tumors.

Evommune, Inc. reported positive findings from its initial proof-of-concept study in humans with EVO756.

CatalYm has reported the successful closure of their Series D financing, raising $150 million.

NexThera Co., Ltd. revealed that it has filed a Phase 1/2a Investigational New Drug application with the U.S. Food and Drug Administration for NT-101.

Zai Lab and argenx Announce China's Approval of Efgartigimod Alfa Subcutaneous Injection for Generalized Myasthenia Gravis.

Eluminex Biosciences Announces Initial Patient Treatment in Phase 1b LOTUS Study of New Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema (DME).